| Emtricitabine/Rilpivirine HCl/Tenofovir Alafenamide Fumarate |
Tablet |
II (Paddle |
75 |
Rilpivirine (RPV): 0.5% Polysorbate 20 in 0.01 N HCl; Emtricitabine (ETC) and Tenofovir alafenamide (TAF): 50 mM Sodium Citrate, pH 5.5, |
RPV: 1000 mL; ETC and TAF: 500 mL |
5, 10, 15, 20, 30 and 45 |
2016/07/28 |
| Emtricitabine/Rilpivirine HCl/Tenofovir Disoproxil Fumarate |
Tablet |
II (Paddle) with sinker |
75 |
0.5%(w/w) polysorbate 20 in 0.01N HCl (pH 2.0) |
1000 |
Emtricitabine and Tenofovir: 5, 10, 15, 20 and 30; Rilpivirine: 10, 20, 30, 45, 60, 75, 90 and 120 |
2015/01/15 |
| Emtricitabine/Tenofovir Alafenamide Fumarate |
Tablet |
II (Paddle |
75 |
50 mM Sodium Citrate buffer, pH 5.5 |
500 |
5, 10, 15, 20, 30 and 45 |
2016/07/28 |
| Emtricitabine/Tenofovir Disoproxil Fumarate |
Tablet |
II (Paddle) |
50 |
0.01 N HCl |
900 |
5, 10, 15, 30 and 45 |
2007/01/03 |
| Enalapril Maleate |
Tablet |
|
|
Refer to USP |
|
|
2008/09/03 |
| Encorafenib |
Capsule |
II (Paddle) with sinker |
100 |
Ammonium acetate buffer, pH 4.5 |
900 |
15, 30, 45 and 60 |
2025/03/17 |
| Ensartinib Hydrochloride |
Capsule |
II (Paddle) with sinker |
50 |
0.1 N HCl |
900 |
15, 20, 30, 45 and 60 |
2026/01/28 |
| Entacapone |
Tablet |
II (Paddle) |
50 |
Phosphate Buffer, pH 5.5 |
900 |
10, 20, 30 and 45 |
2004/01/29 |
| Entecavir |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Entrectinib |
Capsule |
II (Paddle) with Sinker |
75 |
50 mM Potassium Phosphate, pH 6.0 with 0.374% w/v polysorbate 80 |
1000 |
15, 20, 30, 45, 60 and 75 |
2021/08/19 |
| Enzalutamide |
Tablet |
II (Paddle) |
50 |
Phosphate Buffer, pH 7.5 |
900 |
5, 10, 15, 20, 30 and 45 |
2022/05/12 |
| Enzalutamide |
Capsule |
II (Paddle) with sinker |
50 |
Tier 1 Medium: 0.3%
cetyl trimethyl ammonium bromide (CTAB) in 0.1
N HCl;Tier 2 Medium: 0.3% CTAB in 0.1
N HCl containing Pepsin 600,000 USP units/L. |
900 |
10, 15, 20, 30 and 45 |
2015/05/28 |
| Eplerenone |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Eprosartan Mesylate |
Tablet |
II (Paddle) |
75 |
0.2 M Phosphate Buffer, pH 7.5 |
1000 |
15, 30, 45 and 60 |
2008/07/14 |
| Eprosartan Mesylate/Hydrochlorothiazide |
Tablet |
II (Paddle) |
75 |
0.2 M Phosphate Buffer, pH 7.5 |
1000 |
10, 20, 30 and 45 |
2008/02/19 |
| Erdafitinib |
Tablet |
I (Basket) |
75 |
0.01 N HCl, pH 2 |
500 |
5, 10, 15, 20, 30, 45 and 60 |
|
| Ergocalciferol |
Capsule |
II (Paddle) |
100 |
0.5 N NaOH with 10% Triton-X-100 |
500 |
15, 30, 45, 60 and 90 |
2010/08/05 |
| Erlotinib HCl |
Tablet |
II (Paddle) |
75 |
0.02% Tween 80 in 0.01 N HCl |
1000 |
5, 10, 15, 20, 30 and 45 |
2018/10/18 |
| Ertugliflozin |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2025/06/23 |
| Erythromycin |
Tablet |
|
|
Refer to USP |
|
|
2015/12/24 |